Mallinckrodt Stock Analysis, Valuation (NYSE:MNK)

Add to My Stocks
$14.57 $0 (0%) MNK stock closing price Mar 21, 2018 (Closing)
Watch Robo Advisor Video of MNK Stock Analysis
Updated on : Mar 21, 2018
previous close
MNK 14.6 (0%)
S&P 500 2716.9 (0%)
Closing Price On: Mar 20, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Generic Drugs
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Operating Margins
Net Margins
PE Valuation
PS Valuation
Recent Growth
High Debt Burden
Cash Flow
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Mallinckrodt Stock Analysis

355 6 2

View the Mallinckrodt stock analysis video on Amigobulls. This is our analyst opinion covering the buy and sell arguments for MNK stock.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Mallinckrodt PLC Stock Rating 3.9/5

Amigobulls MNK stock analysis takes into account various financial ratios like relative valuation, Mallinckrodt revenue, growth and return on equity based on latest quarter 2017 Q3 financial statements. We also check Mallinckrodt dividend performance. We also use relative valuation metrics like PE ratio and price to sales ratio for Mallinckrodt valuation analysis. Mallinckrodt stock rating is our opinion about the business fundamentals of the company.

Should you buy MNK stock?

  • Mallinckrodt had a healthy average operating margin of 13% over the last 4 quarters.
  • LTM Net margins were good at 66.3% for Mallinckrodt.
  • The Mallinckrodt stock currently trades at a price to earnings ratio of 2.2. We rate this as a positive, compared to the industry average of 23.7.
  • When compared with the Medical-Generic Drugs industry average PS ratio of 6, the price-to-sales ratio of 0.5 for MNK stock is attractive.
  • Mallinckrodt generates a high return on invested capital of 2.4%.
  • Mallinckrodt has a good Return On Equity (ROE) of 39.8%.
  • The company has a healthy free cash flow margin of 30.8%.

Should you sell MNK stock?

  • Mallinckrodt sales shrank by -4.5% year-over-year in 2017 Q4.
  • Mallinckrodt has a debt/equity ratio of  1.03, which is worse than the average in the Medical sector.
  • The company has an operating cash flow which is 0.2 times the net income. This is not a healthy sign.

Comments on this video and Mallinckrodt stock

Amigobulls Mallinckrodt stock analysis helps in evaluating the financial statements of a company to arrive at a conclusion about the fair value of MNK stock. Company's fundamentals remain one of the key driver of MNK stock and helps investors in making good buy and sell decision.

Mallinckrodt revenue growth and profit or net income are the main underlying forces which could detremine the direction of the share price. Along with fundamentals, investors can utilize technical analysis to get a better idea about the price trend of Mallinckrodt stock.